|
KMID : 0388019940050020049
|
|
Korean Journal Gynecologic Oncology and Colposcopy
1994 Volume.5 No. 2 p.49 ~ p.58
|
|
|
Efficacy of Tumor Markers, Ca 125 CA 15-3 and UGF in Differentiating Malignant from Benign Pelvic Tumors
|
|
|
|
|
Abstract
|
|
|
Objective:
@EN The purpose of our study was to evaluate wheather the combined use of various tumor markers, CA 125, CA 15-3 and UGF( urinary gonadotropin fragment) could improve the efficacy for differentiating for differentiating malignant from benign
pelvic
tumors.
@EN Study design: Preoperative samples were collected from 109 patients with pelvic masses. Using immunoradiometric assays, CA 15-3 and using enzyme immunoassay UGF were measured.
@ES Results:
@EN Serum CA 125 levels were elevated above 35 U/ml in 78.1% and above 65 U/ml in 62.5% of 32 patients with malignant pelvic masses, and in 20.3%, and 8.7% of 69 patients with benign pelvic masses, respectively. Elevation of CA 15-3(>30 U/ml) and
UGF(>3
fmol/mgCr) levels occured in 29% and 50% of patients with malignancies, and in 1.7%, and 6.6% of patients with benign masses, respectively. Sensitivity of CA 125 were higher than those of CA 15-3 and UGF. However specificity of CA 125 was lower
than
those of other two markers. Sensitivity and Specificity of UGF were located between those of CA 125 and CA 15-3. For differentiating malignant from benign, among patients below 50 years of age, coordinate elevation of CA 125(>35 U/ml) and, CA
15-3(>30
U/ml) or UGF(3> fmol/mgCr) revealed with a sensitivity of 50% and a specificity of 100% in malignant pelvic masses, and with 57% of sensitivity and 100% of specificity in malignant epithelial ovarian cancer, respectively.
@ES Conclusion:
@EN Combined use of CA 125, CA 15-3 and UGF could obtain an acceptable sensigtivity and an excellent specificity in differentiating malignant from benign pelvic masses, especially among patients below 50 years of age.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|